A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge

NCT06301776 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

560

Enrollment

OTHER

Sponsor class

Conditions

Brain Disease
Vertebral Artery Stenosis

Interventions

DRUG: Ticagrelor

Sponsor

The Fourth Affiliated Hospital of China Medical University